Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab alone or with ligufalimab vs pembrolizumab in first-line R/M HNSCC
NCT07264075Phase 3Recruiting
- Sponsor
- GORTEC
- Start
- May 2026
- Primary completion
- May 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Started May 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07264075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264075.